Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report
BACKGROUND: Programmed cell death protein-1 (PD-1) or its ligand PD-L1 monoclonal antibodies, opening a new era of tumor immunotherapy, and they have significantly improved the overall survival of many patients with advanced solid tumors. However, in addition to its effectiveness, we should also pay...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459630/ https://www.ncbi.nlm.nih.gov/pubmed/36093549 http://dx.doi.org/10.21037/tcr-22-426 |